Overview

Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2038-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)

Phase:

Phase 2

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Fludarabine